Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammation Eye Pain Clear all
Completed Phase 3 Interventional Results available

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT01591161
View directory record Official record
Conditions
Cataract, Inflammation, Surgery
Interventions
Mapracorat, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

NCT03499873
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac 0.3% Oph Susp, Placebos, Nepafenac 0.3% Oph Susp (reference)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

NCT04249076
View directory record Official record
Conditions
Cataract
Interventions
Clobetasol Propionate, Vehicle
Drug
Lead sponsor
Salvat
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Sun City, Arizona • Hemet, California • Inglewood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT05626478
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT01666210
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
OTX-DP (Dexamethasone punctum plug), Placebo Vehicle Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

NCT03192137
View directory record Official record
Conditions
Inflammation and Pain Associated With Cataract Surgery
Interventions
ISV-305, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
17 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT01591655
View directory record Official record
Conditions
Cataract, Inflammation, Surgery
Interventions
Mapracorat, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 24, 2026, 4:06 PM EDT
Completed No phase listed Observational

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

NCT04975971
View directory record Official record
Conditions
Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating KeratoPlasty, Nuclear Cataract, Cortical Cataract, Cataract Senile
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery

NCT00333918
View directory record Official record
Conditions
Pain, Inflammation
Interventions
bromfenac ophthalmic solution, placebo comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

NCT02508337
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT06128369
View directory record Official record
Conditions
Inflammation Eye Pain, Postoperative Cataract
Interventions
OCS-01, Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Glendale, California • Inglewood, California • Newport Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

NCT04130802
View directory record Official record
Conditions
Inflammation Corneal, Pain, Postoperative
Interventions
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL, Placebo
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 4 Interventional

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

NCT04563299
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Phase 4 Interventional

Dextenza in the Post-op Management of Vitreoretinal Surgeries

NCT04371445
View directory record Official record
Conditions
Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain, Post-Operative Inflammation
Interventions
Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 4 Interventional

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

NCT04316936
View directory record Official record
Conditions
Cataract Surgery
Interventions
Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension, Prednisolone Acetate 1%
Drug
Lead sponsor
Silverstein Eye Centers
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

NCT03180255
View directory record Official record
Conditions
Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Interventions
Dexamethasone phosphate, Placebo
Combination Product · Other
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of SDN-037

NCT03426267
View directory record Official record
Conditions
Inflammation and Pain Associated With Ocular Surgery
Interventions
SDN-037, Placebo
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Chandler, Arizona • Mesa, Arizona • Prescott, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

NCT02065375
View directory record Official record
Conditions
Inflammation and Pain Following Ocular Surgery
Interventions
Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Fort Myers, Florida • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 24, 2026, 4:06 PM EDT
Enrolling by invitation Phase 3 Interventional

A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery

NCT07832552
View directory record Official record
Conditions
Postoperative Ocular Inflammation, Postoperative Ocular Pain
Interventions
Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension)
Procedure · Drug
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects

NCT04324359
View directory record Official record
Conditions
Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Interventions
SURF-201, Placebo
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Hemet, California • Murrieta, California • Brooksville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 24, 2026, 4:06 PM EDT
Not listed Phase 4 Interventional

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

NCT04501367
View directory record Official record
Conditions
Vitrectomy, Macular Pucker, Retinal Edema
Interventions
Dexamethasone Intracanalicular Insert, 0.4 mg, Prednisone acetate 1%
Drug
Lead sponsor
Kovach Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Elmhurst, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

NCT04273282
View directory record Official record
Conditions
Cataract
Interventions
Dexycu intracameral dexamethasone, Prednisolone Acetate
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Laguna Hills, California • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

NCT03192150
View directory record Official record
Conditions
Inflammation and Pain Associated With Cataract Surgery
Interventions
ISV-305, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
17 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation

NCT04222725
View directory record Official record
Conditions
Post Surgical Ocular Inflammation
Interventions
TRS01 eye drops, Placebo eye drops
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Inglewood, California • Petaluma, California • Washington, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 24, 2026, 4:06 PM EDT